Growing Healthcare Impact: 14 Clinical Trials Worldwide
See details of those trials below, from objective to status, design, endpoint, and more.
- Why RapidAI
- Clinical Trials
RapidAI Has Been Used in the Most Influential Stroke Clinical Trials Around the World
Our clinical trials are producing high-quality data for healthcare decision making, and are helping us continue to redefine stroke care. They help us evaluate stroke interventions and disease treatment safety and efficacy.
SELECT TRIAL
CRISP
OBJECTIVE
Determine if Rapid CTP can help physicians accurately predict response to recanalization in AIS patients undergoing endovascular therapy.
STATUS
Patients with a Target mismatch profile on Rapid who were treated up to 18 hours after stroke onset had a favorable clinical response rate of 83% following reperfusion.
SELECTION
Rapid imaging for 100% of patients
DESIGN
Prospective, observational
TX WINDOW
0–18 hours
ENDPOINT
30-day NIHSS
DAWN
OBJECTIVE
Evaluate if Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in selected AIS patients.
STATUS
Early termination for efficacy. Highest rate of clinical benefit (36% absolute risk reduction) in any endovascular stroke trial.
SELECTION
Rapid imaging for 100% of patients
DESIGN
PROBE, adaptive design
TX WINDOW
6–24 hours
ENDPOINT
90-day average weighted mRS
DEFUSE 2
OBJECTIVE
Determine if perfusion imaging can help identify which patients, who are ineligible or failed IV tPA, are most likely to benefit from an endovascular clot removal procedure.
STATUS
Complete
SELECTION
Rapid imaging for 100% of patients
DESIGN
Prospective, observational
TX WINDOW
0–12 hours
ENDPOINT
30-day NIHSS
DEFUSE 3
OBJECTIVE
Assess the safety and efficacy of thrombectomy in carefully selected patients in an extended time window.
STATUS
Stopped for efficacy
SELECTION
Rapid imaging for 100% of patients
DESIGN
PROBE, adaptive design
TX WINDOW
6–16 hours
ENDPOINT
90-day mRS
EXTEND
OBJECTIVE
Determine if AIS patients selected with significant penumbral mismatch (measured by MRI criteria) will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.
STATUS
Stopped for efficacy
SELECTION
Rapid imaging for 100% of patients
DESIGN
Prospective, randomized, double-blinded
TX WINDOW
3–9 hours
ENDPOINT
mRS 0-1 at 90 days
EXTEND-AI
OBJECTIVE
Determine whether more advanced imaging selection, newer generation devices, and earlier intervention improve outcomes.
STATUS
Early termination for efficacy. Highest rate of favorable clinical outcome (71%) in any endovascular stroke trial.
SELECTION
Rapid imaging for 100% of patients
DESIGN
PROBE, adaptive design
TX WINDOW
0–6 hours
ENDPOINT
Reperfusion at 24 hrs; NIHSS reduction ≥ 8 or Day 3 NIHSS 0 or 1
EXTEND-AI-TNK
OBJECTIVE
Assess the efficacy and safety of intravenous tenecteplase vs. tPA for bridging therapy prior to early window thrombectomy.
STATUS
Complete
SELECTION
Rapid imaging
DESIGN
Prospective, randomized, open-label, blinded endpoint (PROBE)
TX WINDOW
0–6 hours
ENDPOINT
Proportion of patients with substantial angiographic reperfusion (as defined by mTICI score of 2b/3) at initial angiogram
FRAME
OBJECTIVE
Investigate the relationship between the success of mechanical thrombectomy performed within 6 hours after onset, the rate of good functional outcome at 3 months, and the presence or absence of Target mismatch on acute multimodal imaging.
STATUS
Complete
SELECTION
Rapid imaging for 100% of patients
DESIGN
Prospective, observational
TX WINDOW
0–6 hours
ENDPOINT
90-day mRS
ImPACT-P
OBJECTIVE
Assess the efficacy of augmenting CBF to preserve the penumbra in AIS patients.
STATUS
Enrolling
SELECTION
Rapid imaging for 100% of patients
DESIGN
Prospective, randomized, double-blind
TX WINDOW
5 days
ENDPOINT
5-day infarct volume
RESILIENT
OBJECTIVE
Determine if AIS patients due to LVO, treated with combined IV tPA and Solitaire within 6 hours of symptom onset have less stroke-related disability than those patients treated with IV tPA alone.
STATUS
Complete
SELECTION
Rapid imaging selection
DESIGN
PROBE, sequential design
TX WINDOW
0–6 hours
ENDPOINT
90-day mRS
SELECT
OBJECTIVE
Evaluate different imaging selection methodologies and identify which method provides the highest predictive ability in the selection of AIS patients for IAT.
STATUS
Complete
SELECTION
Rapid imaging for 100% of patients
DESIGN
Prospective, observational
TX WINDOW
0–24 hours
ENDPOINT
90-day mRS
SELECT2
OBJECTIVE
Evaluate the safety and efficacy of endovascular thrombectomy in AIS patients with a large core.
STATUS
Enrolling
SELECTION
Rapid imaging
DESIGN
Prospective, randomized, assessor-blinded controlled trial
TX WINDOW
0–24 hours
ENDPOINT
90-day mRS
SWIFT PRIME
OBJECTIVE
Determine if AIS patients due to LVO, treated with combined IV tPA and Solitaire within 6 hours of symptom onset have less stroke-related disability than those patients treated with IV tPA alone.
STATUS
Early termination for efficacy. Second highest rate of favorable clinical outcome in any endovascular stroke trial.
SELECTION
Rapid imaging for 80% of patients
DESIGN
PROBE, sequential design
TX WINDOW
0–6 hours
ENDPOINT
90-day mRS
TIMELESS
OBJECTIVE
Evaluate the efficacy and safety of Tenecteplase compared with placebo in patients with AIS and evidence of salvageable tissue on their baseline imaging.
STATUS
Enrolling
SELECTION
Rapid imaging
DESIGN
Prospective, randomized, open-label, double-blind
TX WINDOW
4.5–24 hours
ENDPOINT
90-day mRS
